• Je něco špatně v tomto záznamu ?

Association between ustekinumab therapy and changes in specific anti-microbial response, serum biomarkers, and microbiota composition in patients with IBD: A pilot study

F. Rob, D. Schierova, Z. Stehlikova, J. Kreisinger, R. Roubalova, S. Coufal, M. Mihula, Z. Jackova, M. Kverka, T. Thon, K. Kostovcikova, L. Bajer, P. Drastich, JT. Hercogova, M. Novakova, M. Kolar, M. Vasatko, M. Lukas, H. Tlaskalova-Hogenova, Z....

. 2022 ; 17 (12) : e0277576. [pub] 20221230

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004859

BACKGROUND: Ustekinumab, is a new therapy for patients with IBD, especially for patients suffering from Crohn's disease (CD) who did not respond to anti-TNF treatment. To shed light on the longitudinal effect of ustekinumab on the immune system, we investigated the effect on skin and gut microbiota composition, specific immune response to commensals, and various serum biomarkers. METHODOLOGY/PRINCIPAL FINDINGS: We recruited 11 patients with IBD who were monitored over 40 weeks of ustekinumab therapy and 39 healthy controls (HC). We found differences in the concentrations of serum levels of osteoprotegerin, TGF-β1, IL-33, and serum IgM antibodies against Lactobacillus plantarum between patients with IBD and HC. The levels of these biomarkers did not change in response to ustekinumab treatment or with disease improvement during the 40 weeks of observation. Additionally, we identified differences in stool abundance of uncultured Subdoligranulum, Faecalibacterium, and Bacteroides between patients with IBD and HC. CONCLUSION/SIGNIFICANCE: In this preliminary study, we provide a unique overview of the longitudinal monitoring of fecal and skin microbial profiles as well as various serum biomarkers and humoral and cellular response to gut commensals in a small cohort of patients with IBD on ustekinumab therapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004859
003      
CZ-PrNML
005      
20230425171748.0
007      
ta
008      
230418s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0277576 $2 doi
035    __
$a (PubMed)36584073
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Rob, Filip $u Second Faculty of Medicine, Dermatovenerology Department, University Hospital Bulovka, Charles University, Prague, Czech Republic
245    10
$a Association between ustekinumab therapy and changes in specific anti-microbial response, serum biomarkers, and microbiota composition in patients with IBD: A pilot study / $c F. Rob, D. Schierova, Z. Stehlikova, J. Kreisinger, R. Roubalova, S. Coufal, M. Mihula, Z. Jackova, M. Kverka, T. Thon, K. Kostovcikova, L. Bajer, P. Drastich, JT. Hercogova, M. Novakova, M. Kolar, M. Vasatko, M. Lukas, H. Tlaskalova-Hogenova, Z. Jiraskova Zakostelska
520    9_
$a BACKGROUND: Ustekinumab, is a new therapy for patients with IBD, especially for patients suffering from Crohn's disease (CD) who did not respond to anti-TNF treatment. To shed light on the longitudinal effect of ustekinumab on the immune system, we investigated the effect on skin and gut microbiota composition, specific immune response to commensals, and various serum biomarkers. METHODOLOGY/PRINCIPAL FINDINGS: We recruited 11 patients with IBD who were monitored over 40 weeks of ustekinumab therapy and 39 healthy controls (HC). We found differences in the concentrations of serum levels of osteoprotegerin, TGF-β1, IL-33, and serum IgM antibodies against Lactobacillus plantarum between patients with IBD and HC. The levels of these biomarkers did not change in response to ustekinumab treatment or with disease improvement during the 40 weeks of observation. Additionally, we identified differences in stool abundance of uncultured Subdoligranulum, Faecalibacterium, and Bacteroides between patients with IBD and HC. CONCLUSION/SIGNIFICANCE: In this preliminary study, we provide a unique overview of the longitudinal monitoring of fecal and skin microbial profiles as well as various serum biomarkers and humoral and cellular response to gut commensals in a small cohort of patients with IBD on ustekinumab therapy.
650    _2
$a lidé $7 D006801
650    _2
$a ustekinumab $x terapeutické užití $7 D000069549
650    _2
$a pilotní projekty $7 D010865
650    _2
$a inhibitory TNF $7 D000079424
650    12
$a Crohnova nemoc $x terapie $7 D003424
650    _2
$a biologické markery $7 D015415
650    12
$a mikrobiota $7 D064307
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Schierova, Dagmar $u Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Stehlikova, Zuzana $u Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Kreisinger, Jakub $u Faculty of Science, Department of Zoology, Charles University, Prague, Czech Republic
700    1_
$a Roubalova, Radka $u Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic $1 https://orcid.org/0000000292984734
700    1_
$a Coufal, Stepan $u Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Mihula, Martin $u Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Jackova, Zuzana $u Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Kverka, Miloslav $u Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Thon, Tomas $u Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Kostovcikova, Klara $u Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Bajer, Lukas $u Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic $u Hepatogastroenterology Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Drastich, Pavel $u Hepatogastroenterology Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Hercogova, Jana Tresnak $u Second Faculty of Medicine, Dermatovenerology Department, University Hospital Bulovka, Charles University, Prague, Czech Republic
700    1_
$a Novakova, Michaela $u Second Faculty of Medicine, Dermatovenerology Department, University Hospital Bulovka, Charles University, Prague, Czech Republic
700    1_
$a Kolar, Martin $u ISCARE a.s., IBD Clinical and Research Centre, Prague, Czech Republic
700    1_
$a Vasatko, Martin $u ISCARE a.s., IBD Clinical and Research Centre, Prague, Czech Republic
700    1_
$a Lukas, Milan $u ISCARE a.s., IBD Clinical and Research Centre, Prague, Czech Republic $u General University Hospital and First Faculty of Medicine, Institute of Medical Biochemistry and Laboratory Diagnostics, Charles University, Prague, Czech Republic
700    1_
$a Tlaskalova-Hogenova, Helena $u Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Jiraskova Zakostelska, Zuzana $u Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic $1 https://orcid.org/0000000266958188
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 17, č. 12 (2022), s. e0277576
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36584073 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425171745 $b ABA008
999    __
$a ok $b bmc $g 1925134 $s 1191068
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 17 $c 12 $d e0277576 $e 20221230 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace